36.30
-0.06 (-0.17%)
前收盘价格 | 36.36 |
收盘价格 | 36.43 |
成交量 | 575,732 |
平均成交量 (3个月) | 456,351 |
市值 | 1,745,354,752 |
市盈率 (P/E TTM) | 12.06 |
价格/销量 (P/S) | 2.63 |
股市价格/股市净资产 (P/B) | 2.41 |
52周波幅 | |
利润日期 | 26 Feb 2025 - 3 Mar 2025 |
营业毛利率 | 21.80% |
营业利益率 (TTM) | 29.83% |
稀释每股收益 (EPS TTM) | 3.01 |
季度收入增长率 (YOY) | 5.90% |
季度盈利增长率 (YOY) | -17.90% |
总债务/股东权益 (D/E MRQ) | 86.56% |
流动比率 (MRQ) | 3.43 |
营业现金流 (OCF TTM) | 208.23 M |
杠杆自由现金流 (LFCF TTM) | 8.61 M |
资产报酬率 (ROA TTM) | 8.67% |
股东权益报酬率 (ROE TTM) | 23.85% |
市场趋势
短期 | 中期 | ||
行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
股票 | Amphastar Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
分析师共识 | 1.5 |
内部交易活动 | NA |
价格波动 | 4.5 |
技术平均移动指标 | -2.5 |
技术振荡指标 | -2.5 |
平均 | 0.25 |
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
|
部门 | Healthcare |
行业 | Drug Manufacturers - Specialty & Generic |
投资方式 | Small Core |
内部持股比例 | 22.41% |
机构持股比例 | 75.13% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Td Asset Management Inc | 30 Sep 2024 | 2,135,038 |
Epoch Investment Partners, Inc. | 30 Sep 2024 | 1,191,110 |
52周波幅 | ||
中 | 55.00 (51.52%) | |
总计 | 1 购买 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Wells Fargo | 22 Nov 2024 | 55.00 (51.52%) | 购买 | 45.46 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合